Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KT News out!!
7:20a ET 12/15/2020 - Globe Newswire
BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market
Mentioned: BIEL
via NewMediaWire -- BioElectronics Corporation (OTC PINK: BIEL), (www.bielcorp.com) is pleased to announce that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
The agreement incorporates BioElectronics' ActiPatch(R) technology into KT Health's KT Recovery+(R) product line, which will be marketed under the proprietary trade name KT Recovery+ Wave(TM). KT Health will leverage BioElectronics' FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain. As part of this agreement BioElectronics will cease active promotion of the brand name ActiPatch in North America. Existing channel partners in the USA will continue promoting the ActiPatch brand name, while BioElectronics will continue expanding its network of international distributors for ActiPatch.
Keith Nalepka, VP Sales and Marketing for BioElectronics, said, "This is an amazing win for our Company. KT Recovery+ Wave(TM) combines our drug-free pain relief technology with the brand power and adhesives expertise of the recognized leader in drug-free pain treatment and recovery. Consumers will be able to easily place the KT Recovery+ Wave(TM) device anywhere on the body to treat musculoskeletal pain. We believe KT Health is an excellent match for our technology and can effectively leverage its large customer base that is already comfortable with wearables."
Greg Venner, CEO of KT Health, commented, "We are extremely pleased to be partnering with BioElectronics on such an innovative and effective product. KT Recovery+ Wave(TM) allows KT Health to broaden our drug-free pain relief options, expanding our product line into the chronic pain category. We look forward to a long and productive partnership with BioElectronics."
About BioElectronics Corporation
Headquartered in Frederick, Maryland, and founded in 2000, BioElectronics Corporation is the leading company in the field on non-invasive electroceutical medical devices. BioElectronics is the maker of disposable, drug-free, pain therapy devices: ActiPatch(R) Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx(R) Therapy for postoperative pain and chronic wound care.
About KT Health, LLC:
Based in American Fork, Utah and founded in 2008, KT Health, LLC has revolutionized sports medicine with some of the most advanced drug-free pain relief and recovery products in the industry. KT Health's products have become the athlete's choice for drug free pain relief and injury management. The Company currently designs, develops, and distributes a variety of kinesiology tape lines, including KT Tape(R) Original (cotton) and KT Tape(R) Pro(TM) (synthetic), as well as a line of performance and recovery products. KT Health is the largest kinesiology tape manufacturer in the world, available in 42,000+ domestic retail locations and 40 countries. For more information, visit www.kttape.com.
Forward Looking Statements
Certain information set forth in this email contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact:
Bioelectronics Market Global Growth Analysis and Forecast to 2024 | Top Players (Bioelectronics Corporation, Avago, Honeywell International, Danaher Corporations, More)
https://canaanmountainherald.com/uncategorized/82043/bioelectronics-market-global-growth-analysis-and-forecast-to-2024-top-players-bioelectronics-corporation-avago-honeywell-international-danaher-corporations-more/
8's gone..
WOW 45M/0.0008...
We finished our 3rd @RecoveryRx training class with Medi-Launch partners & we now have 150+ reps active in the field selling product & changing the standard of care for post op pain. This happened tremendously faster than anticipated!! #growth #painfree #RecoveryRX #teambiel
We finished our 3rd @RecoveryRx training class with Medi-Launch partners & we now have 150+ reps active in the field selling product & changing the standard of care for post op pain. This happened tremendously faster than anticipated!! #growth #painfree #RecoveryRX #teambiel
— BioElectronics Corp (@BielCorp) October 13, 2020
Hmm... 45M shares trdae within 30min...
Buyback Rumor from Biel Twitter
https://twitter.com/rumormurmurbuzz/status/1303417758743293952?s=21
From Bioelectronics Twitter
Order was for 22k boxes and DFUs. Ordered 5k more boxes & DFUs today. As an OEM, we don't package all products. The 120k discussed in the Chairman's letter are NOT part of this box order. #revenue #teambiel #OEM #shippingworldwide
This particular order was for 22k boxes and DFUs. Ordered 5k more boxes & DFUs today. As an OEM, we don't package all products. The 120k discussed in the Chairman's letter are NOT part of this box order. #revenue #teambiel #OEM #shippingworldwide
— BioElectronics Corp (@BielCorp) September 9, 2020
This particular order was for 22k boxes and DFUs. Ordered 5k more boxes & DFUs today. As an OEM, we don't package all products. The 120k discussed in the Chairman's letter are NOT part of this box order. #revenue #teambiel #OEM #shippingworldwide
— BioElectronics Corp (@BielCorp) September 9, 2020
HKIBC All About Money features Rob Royea, Cyrcadia Asia…
https://cyrcadia.asia/2018/10/31/hkibc-all-about-money-features-rob-royea-cyrcadia-asia/#more-676
$18.29 is Actipatch Refill price ..Reg Knee Actipatch $30.49
Q2 finacials report out..
https://www.otcmarkets.com/stock/LLBO/disclosure
New twitters from Rob Royar
科大讯飞股份有限公司 & Cyrcadia Asia, Ltd. team up for early #breastcancer detection through AI enabled technology! https://t.co/ozkIxQCgjC
— Rob Royea (@RobRoyea) July 20, 2018
China strives to lower cost of cancer drugs as disease rates soar https://t.co/iS8NJl0Utz via @pharmaphorum @Cyrcadia @IFLYTEK #breasthealth #breastdensity #breastcancer
— Rob Royea (@RobRoyea) July 20, 2018
new clinical trial for Cervical Osteoarthritis..
https://clinicaltrials.gov/ct2/show/NCT03542955?term=bioelectronics&rank=5
Migraine trial completed...
https://clinicaltrials.gov/ct2/show/NCT03166046?term=bioelectronics&rank=7
going up..NITE, CANT out of ammo.. IMO
Dilution???
https://www.otcmarkets.com/stock/LLBO/disclosure
2017 Q/3 LLBO AWS 3,138,880,967
2016 LLBO AWS 3,138,880,967
2015 LLBO AWS 3,116,146,720
2014 LLBO AWS 3,046,680,967
https://www.otcmarkets.com/stock/LLBO/disclosure
more update from Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | News | 0 comments
February 27, 2018
Cyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations.
License and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status
Earlier in 2017 CI entered into an Agreement with CA, whereby CA assumed the responsibility and funding of the design, development and delivery of a scalable, commercializable iTBra™ system including upgraded hardware and the full suite of application software as well as automation of our proprietary Artificial Intelligence Analytics. The estimated cost of development with Jabil and Mobile Now is approximately $1.2 to $1.5 million US. As such, the agreement calls for CA to provide timely reporting and status of product development including timelines, milestones and dates of completion and delivery of product (market readiness, product volume availability and delivery terms and schedules).
Many strides have been made in the evolution of the relationship as CA has established its operations, initial staffing and funding. Both CI and CA are in a mode of cooperation, as called for by the Agreement and, presently, both entities are to hold routine meetings where comprehensive updating and reporting will be delivered to CI, enabling implementation of our business, operations and marketing plans. We will be reporting the outcomes of that meeting to move forward on our ability to commercialize the iTBra™ system this year.
Given the above, we would like to update on the internal operations that will allow for CI to “hit the ground running” upon product delivery.
Status of Product Development and Manufacturing
Under CA’s contract with Jabil for the design, development and manufacturing for both entities, CI and CA and according to CA, the development schedule is on track and both CI and CA are expecting functional prototype units for clinical study and market applications in the second half of 2018. Jabil has moved through various levels of development including Engineering Validation (EV) and Design Validation (DV) with Design Verification Testing and Product Compliance Testing as the next and final tasks. From there, the product is released for production (MP Release).
Jabil will manufacture the iTBra™ as the initial vendor for both CI and CA (both companies operating under the global head brand of Cyrcadia Health) hardware at their FDA-approved facility in Shanghai. Full scale manufacturing is scheduled to start in the second half 2018, but in the intervening period, we will be able to obtain fully functional products for pilot launches in the U.S. and other countries.
CA’s other contracted developer, Mobile Now Group, is well down the road of development and testing of the “front end” software application and User Interface (UI). Outcomes of the CA/CI cooperation meetings will provide precise status of development along with timelines and schedules.
*Prototype example of User Interface Screens
Regulatory Clearance, Trials Recap
CI’s current US trial success has allowed us to utilize a Non-Filing Justification (NFJ) with the FDA, under our current FDA 510(k) Class II clearance, enabling CI to go to market. Additionally, CI and CA have contracted with two regulatory advisor contractors to drive to a Class I designation (Over the Counter and direct to consumer markets) allowing for entry into market without the scrutiny of a class II device (Clinical, prescribed by physician market), as the iTBra™ stands now. The intent is launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
The El Camino Hospital and The Ohio State University clinical trials have shown that CI’s scalable device is demonstrating over 84% accuracy, sensitivity and specificity with a 2-hour wear time, vs. the Chronodynamic’s (First Warning System) historic accuracy of 74.5% and a required 48-hour wear time. CI has reengaged with El Camino Hospital to resume (pending CA’s timely product delivery) the paused clinical trials with the new and significantly improved commercializable product. Discussions are underway with the other trial site, The James Cancer center at Ohio State University, to resume the paused trials under the new product design and protocol. A.
Intellectual Property
Since the original CI patents were issued in 2012, the product and artificial intelligence based software has evolved considerably into the wearable and conformable device that it is now. Invention disclosers have been completed and are currently under review by both CI and CA intellectual property counsels. As a result, both CI and CA will own several new patent applications. Those applications can take some years to be examined and approved, but the pending patents themselves will have tangible value to current and potential investors, partners and acquirers. As a result of the deal with CA, CA is also applying for trademarks, designs and patents in multiple countries in the US and Asia, to be assigned to territories that CI serves.
Operations
CI and CA are currently structuring a detailed supply agreement for product delivery including the terms, costs and volumes with timing. Jabil will be a critical element of this agreement and is preparing to collaborate with both CI and CA as the manufacturer on delivery of goods for marketing and sales. This agreement is a critical piece and a significant milestone to realize the conversion to market from design and development. We will deliver more detailed information once the agreement is completed and consummated.
CI is expanding its team with contractors and internal additions. We have retained two groups for marketing/commercialization addressing the consumer/OTC markets: Life Science Strategy Group (LSSG) and the DuPuis Group. LSSG has performed extensive, third party market research for positioning and roll out to the clinical markets. The DuPuis Group has performed deep market research specifically to the consumer/OTC markets, and, as you will see below, has been selected as our strategic partner for commercialization and marketing deployment in the consumer/OTC markets.
For the clinical markets, CI is in discussions with potential strategic partners for the marketing deployment and commercialization for the clinical markets. We will share more in depth information once we have selected that strategic partner.
CI has retained consultant Cheryl Fisher, formerly with the Emergo Group, as our internal Director of Regulatory Affairs, Quality Assurance, and Clinical Affairs (RA/QA/CA). Mrs. Fisher will operate as the conduit between CI and the FDA, as well as manage and guide our Regulatory pathway as described above. Cheryl has worked with the company in an advisory capacity for a number of years and has deep knowledge and familiarity of not only the FDA requirements and processes, but with CI itself.
Finally, CI has retained a consultant to drive the comprehensive processes and agendas currently under way, fulfilling the need for timely execution, team and department accountability, as well as risk management and reporting to the executive team.
More headcount is slated as we prepare to execute our marketing plans. We will introduce you to those capable team members as they come aboard.
Clinical Market Pilots and Market Entry
As previously noted, the first clinical market entries are likely to be with insurance partners working through CA in Asia (and by extension, CI in the U.S.). CI will also launch a lead out pilot in the U.S through Evidation Health (see evidation.com) and its affiliates, Dignity Health and Kaiser Permanente. Evidation, associated with Stanford University and funded by GE Ventures and others, evaluates how the evolution of digital health and wearables can affect change from a care and insurance perspective in the U.S. Through Evidation, the pilot launch will involve a nominal number of subjects with a rapid pace of subscription and validation to both publish and allow leading healthcare providers, insurers and key opinion leaders to observe the value and marketability of the CI solution. This relationship and process provides rapid exposure to the caliber of the business partners and associates of Evidation that would otherwise take years to achieve. These relationships are key to expediting mandates to participants of the insurers and healthcare networks without CI’s need for significant staffing and fundraising to develop an internal salesforce within CI.
OTC and Consumer Commercialization
Our priority now is to finalize and implement our marketing plan enabling the ramp up of sales as soon as possible in 2018 upon product delivery.
We are pleased to report the contracting of the DuPuis Group to implement and execute the OTC/Consumer commercialization plan to put “product on the shelves.” This has been a significant gap for us and their familiarity and deep knowledge of our value proposition is unparalleled. They are an exemplary team to bring us to revenue. More to come as we develop our timing and targets for rollout.
Competitive Analysis
No competitive technologies have materialized that would threaten our business plan. We are confident our intellectual property filings are a significant barrier to market entry and our usage of artificial intelligence software is market leading technology. In addition, our contract for manufacturing in China ensures a high volume competitive product cost.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA. We are committed to ensuring ongoing communication and look forward to demonstrating further success in 2018 and beyond.
Sincerely,
Matt Benardis
CEO
Cyrcadia, Inc.
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | News | 0 comments
February 27, 2018
Cyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations.
License and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status
Earlier in 2017 CI entered into an Agreement with CA, whereby CA assumed the responsibility and funding of the design, development and delivery of a scalable, commercializable iTBra™ system including upgraded hardware and the full suite of application software as well as automation of our proprietary Artificial Intelligence Analytics. The estimated cost of development with Jabil and Mobile Now is approximately $1.2 to $1.5 million US. As such, the agreement calls for CA to provide timely reporting and status of product development including timelines, milestones and dates of completion and delivery of product (market readiness, product volume availability and delivery terms and schedules).
Many strides have been made in the evolution of the relationship as CA has established its operations, initial staffing and funding. Both CI and CA are in a mode of cooperation, as called for by the Agreement and, presently, both entities are to hold routine meetings where comprehensive updating and reporting will be delivered to CI, enabling implementation of our business, operations and marketing plans. We will be reporting the outcomes of that meeting to move forward on our ability to commercialize the iTBra™ system this year.
Given the above, we would like to update on the internal operations that will allow for CI to “hit the ground running” upon product delivery.
Status of Product Development and Manufacturing
Under CA’s contract with Jabil for the design, development and manufacturing for both entities, CI and CA and according to CA, the development schedule is on track and both CI and CA are expecting functional prototype units for clinical study and market applications in the second half of 2018. Jabil has moved through various levels of development including Engineering Validation (EV) and Design Validation (DV) with Design Verification Testing and Product Compliance Testing as the next and final tasks. From there, the product is released for production (MP Release).
Jabil will manufacture the iTBra™ as the initial vendor for both CI and CA (both companies operating under the global head brand of Cyrcadia Health) hardware at their FDA-approved facility in Shanghai. Full scale manufacturing is scheduled to start in the second half 2018, but in the intervening period, we will be able to obtain fully functional products for pilot launches in the U.S. and other countries.
CA’s other contracted developer, Mobile Now Group, is well down the road of development and testing of the “front end” software application and User Interface (UI). Outcomes of the CA/CI cooperation meetings will provide precise status of development along with timelines and schedules.
*Prototype example of User Interface Screens
Regulatory Clearance, Trials Recap
CI’s current US trial success has allowed us to utilize a Non-Filing Justification (NFJ) with the FDA, under our current FDA 510(k) Class II clearance, enabling CI to go to market. Additionally, CI and CA have contracted with two regulatory advisor contractors to drive to a Class I designation (Over the Counter and direct to consumer markets) allowing for entry into market without the scrutiny of a class II device (Clinical, prescribed by physician market), as the iTBra™ stands now. The intent is launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
The El Camino Hospital and The Ohio State University clinical trials have shown that CI’s scalable device is demonstrating over 84% accuracy, sensitivity and specificity with a 2-hour wear time, vs. the Chronodynamic’s (First Warning System) historic accuracy of 74.5% and a required 48-hour wear time. CI has reengaged with El Camino Hospital to resume (pending CA’s timely product delivery) the paused clinical trials with the new and significantly improved commercializable product. Discussions are underway with the other trial site, The James Cancer center at Ohio State University, to resume the paused trials under the new product design and protocol. A.
Intellectual Property
Since the original CI patents were issued in 2012, the product and artificial intelligence based software has evolved considerably into the wearable and conformable device that it is now. Invention disclosers have been completed and are currently under review by both CI and CA intellectual property counsels. As a result, both CI and CA will own several new patent applications. Those applications can take some years to be examined and approved, but the pending patents themselves will have tangible value to current and potential investors, partners and acquirers. As a result of the deal with CA, CA is also applying for trademarks, designs and patents in multiple countries in the US and Asia, to be assigned to territories that CI serves.
Operations
CI and CA are currently structuring a detailed supply agreement for product delivery including the terms, costs and volumes with timing. Jabil will be a critical element of this agreement and is preparing to collaborate with both CI and CA as the manufacturer on delivery of goods for marketing and sales. This agreement is a critical piece and a significant milestone to realize the conversion to market from design and development. We will deliver more detailed information once the agreement is completed and consummated.
CI is expanding its team with contractors and internal additions. We have retained two groups for marketing/commercialization addressing the consumer/OTC markets: Life Science Strategy Group (LSSG) and the DuPuis Group. LSSG has performed extensive, third party market research for positioning and roll out to the clinical markets. The DuPuis Group has performed deep market research specifically to the consumer/OTC markets, and, as you will see below, has been selected as our strategic partner for commercialization and marketing deployment in the consumer/OTC markets.
For the clinical markets, CI is in discussions with potential strategic partners for the marketing deployment and commercialization for the clinical markets. We will share more in depth information once we have selected that strategic partner.
CI has retained consultant Cheryl Fisher, formerly with the Emergo Group, as our internal Director of Regulatory Affairs, Quality Assurance, and Clinical Affairs (RA/QA/CA). Mrs. Fisher will operate as the conduit between CI and the FDA, as well as manage and guide our Regulatory pathway as described above. Cheryl has worked with the company in an advisory capacity for a number of years and has deep knowledge and familiarity of not only the FDA requirements and processes, but with CI itself.
Finally, CI has retained a consultant to drive the comprehensive processes and agendas currently under way, fulfilling the need for timely execution, team and department accountability, as well as risk management and reporting to the executive team.
More headcount is slated as we prepare to execute our marketing plans. We will introduce you to those capable team members as they come aboard.
Clinical Market Pilots and Market Entry
As previously noted, the first clinical market entries are likely to be with insurance partners working through CA in Asia (and by extension, CI in the U.S.). CI will also launch a lead out pilot in the U.S through Evidation Health (see evidation.com) and its affiliates, Dignity Health and Kaiser Permanente. Evidation, associated with Stanford University and funded by GE Ventures and others, evaluates how the evolution of digital health and wearables can affect change from a care and insurance perspective in the U.S. Through Evidation, the pilot launch will involve a nominal number of subjects with a rapid pace of subscription and validation to both publish and allow leading healthcare providers, insurers and key opinion leaders to observe the value and marketability of the CI solution. This relationship and process provides rapid exposure to the caliber of the business partners and associates of Evidation that would otherwise take years to achieve. These relationships are key to expediting mandates to participants of the insurers and healthcare networks without CI’s need for significant staffing and fundraising to develop an internal salesforce within CI.
OTC and Consumer Commercialization
Our priority now is to finalize and implement our marketing plan enabling the ramp up of sales as soon as possible in 2018 upon product delivery.
We are pleased to report the contracting of the DuPuis Group to implement and execute the OTC/Consumer commercialization plan to put “product on the shelves.” This has been a significant gap for us and their familiarity and deep knowledge of our value proposition is unparalleled. They are an exemplary team to bring us to revenue. More to come as we develop our timing and targets for rollout.
Competitive Analysis
No competitive technologies have materialized that would threaten our business plan. We are confident our intellectual property filings are a significant barrier to market entry and our usage of artificial intelligence software is market leading technology. In addition, our contract for manufacturing in China ensures a high volume competitive product cost.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA. We are committed to ensuring ongoing communication and look forward to demonstrating further success in 2018 and beyond.
Sincerely,
Matt Benardis
CEO
Cyrcadia, Inc.
Lifeline Biotechnologies Provides Information to the Public and its Shareholders
GlobeNewswire•February 28, 2018
Reno, NV , Feb. 28, 2018 (GLOBE NEWSWIRE) --
Lifeline Biotechnologies, Inc, (“The Company”) (OTC PINK: LLBO) Provides Information to the Public and Updates It’s Shareholders.
In 2017 Lifeline transferred its previously licensed technology and patents to its affiliate, Cyrcadia, Inc. in exchange for additional equity in Cyrcadia, cash and a promissory note.
As a result of the Lifeline became Cyrcadia’s largest, single shareholder at approximately 40%. At that time the transaction was valued at over twelve million dollars.
Subsequently, Cyrcadia, Inc. licensed Cyrcadia Asia to further develop and finance product upgrades to Cyrcadia, Inc.’s basic capabilities. The increased capabilities include updated and current state of the art technology and efficiencies. These upgrades are nearing completion and product is forecast, by vendors, to be market ready and available by mid-2018. The clinical trials Cyrcadia, Inc. has been conducting at El Camino Hospital and Ohio State University’s Cancer Center, were approximately one-third completed, will be resumed upon product availability, and continued until completion. There have been several positive outcomes derived from the one third completion of the trials, those outcomes, which cannot be described here due to FDA regulations, indicate the trials may be able to be completed in a shorter period of time than originally estimated, possibly completed later this year?
Cyrcadia, Inc. management, in addition to the clinical market potential, has been investigating consumer market opportunities for it early tissue abnormality identification technology. Cyrcadia has retained two medical marketing consulting firms to explore, determine and validate consumer adoption and market potential of its consumer product.
Jim Holmes, Lifeline’s CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually.
Current and futures News updates, posted on CI’s website: cyrcadiahealth.com and under “News” will be posted on Lifeline’s Cyrcadia/News.
https://www.elcaminohospital.org/about-us/clinical-trials/cancer/circadian-thermal-sensing
Thank you for sharing info....
Andy Whelan, President BioElectronics Updates Uptick Newswire “Stock Day” Listeners
•November 20, 2017Comment
Phoenix, AZ , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Uptick Newswire announces interview by host Everett Jolly of returning guest Andy Whelan President of BioElectronics Corp. (OTC: BIEL, the “Company”). Starting off the interview, Mr. Whelan presented an overview of the Company’s pain products, its domestic and international sales, and clinical trials status. The interview may be heard at https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-2
BioElectronics has US FDA market clearance for two wearable OTC neurological medical devices, significant international distributors, and a technology platform for a host of additional products. The current developed product line includes:
RecoveryRx® for Postoperative and Chronic Wounds,
Allay® Menstrual Pain Therapy,
Smart Insole™ for Heel Pain; and,
ActiPatch® Musculoskeletal Pain Therapy.
Our neurological disorder technology platform will produce without burdensome expense products for fibromyalgia, overactive bladder, diabetic neuropathy, chronic tinnitus,migraine headaches (clinical study currently being finalized) etc.
We are launching US sales through a leading wholesaler that distributes generic, brand, specialty, and over-the-counter pharmaceutical products to over 10,000 retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices. Additionally, we expect to have product in at least one of the major drugstoresand several mini chains in 2018.
We will be promoting a money back guarantee on the 30-Day ActiPatch® Musculoskeletal Pain Therapy device by packaging it with the 7-Day Trial device. Try the 7-Day trial device and if you are not satisfied return the trial unit and get a full refund.
International sales are progressing well with a new distributor for Spain and Portugal, an expansion of PharmEvo,our Vietnam distributor, into Cambodia and Maldives. PharmEvo is also contracting for additional Southeast Asia territories of the Philippines, Pakistan, Indonesia, and Malaysia.
In closing Andy stated, “We have an outstanding product line making BioElectronics a very substantial company without additional expense and debt. We have a pipeline of products that we just pump out and make it a very substantial company without incurring additional expense and debt.”
should read this article about iTBra.
https://newsroom.cisco.com/feature-content?type=webcontent&articleId=1846837
GLOBAL HEALTHCARE ARTIFICIAL INTELLIGENCE MARKET 2017- IBM WATSON HEALTH, AICURE, ATOMWISE, CYRCADIA HEALTH, LIFEGRAPH, MODERNIZING MEDICINE
http://publicistreport.com/life-science/healthcare/global-healthcare-artificial-intelligence-market-2017.html
Agree...Fake NITE BID and ASK
NITE 30M/0.00011 BID NITE 28M/0.0012ASK
see below L2.. 0.001083?? LOL
Bioelectronics Corp. (PC) Trades
4
Follow BIEL
Level 3 Montage
Bioelectronics Corp. (PC…
?
Num Exch. Price Size Type C T Bid Offer Time Buy Sell ? Buy Ind. Buy Vol. Sell Vol. ? Vol.
65 nasd 0.001083 40,003,000 avg. 0.0011 0.0012 11:40:03 40,003,000
64 nasd 0.0011 40,000,000 0.0011 0.0012 11:39:29 40,000,000
63 nasd 0.0011 6,000,000 0.0011 0.0012 11:34:56 6,000,000
62 nasd 0.001083 25,000,000 avg. 0.0011 0.0012 11:33:39 25,000,000
BIEL short squeeze
http://ih.advfn.com/p.php?pid=nmona&article=74044514
The combination of the BULLISH rating and the high degree of shorting create a relatively unique condition that could see the PPS of both Companies sky rocket at any minute. An optimistic market and a short squeeze both driving buying and a rapidly increasing PPS.
Other companies on the OTC Short Report Most Shorted list include:
Vapor Group, Inc . (USOTC: VPOR)
Bioelctronics Corp (USOTC: BIEL)
Wall Street Corner Report is the premier discovery site for promising, yet undiscovered small and micro-cap stocks featuring opportunities in an ethical, professional, and responsible manner. We're not fiendishly 'short' sighted nor are we here to dream the impossibly 'long' dream. We take a practical view on the big ideas of well-intentioned management and look to profit on each reasonably achievable step the well intentioned mangers take toward their big ideas.
http://www.wallstreetcornerreport.com/more-news/
0.00128/35M traded today.. LOL
http://ih.advfn.com/stock-market/USOTC/bioelectronics-corp-pc-BIEL/trades
LOL MM's play... NITE transfer each...
BioElectronics Appoints an Indian Subcontinent Distributor
Marketwired MarketwiredMarch 6, 2017Comment
FREDERICK, MD--(Marketwired - Mar 6, 2017) - BioElectronics Corporation ( OTC PINK : BIEL ), www.bielcorp.com is the leading maker of advanced drug-free pain management medical devices.
The company's recent US FDA over-the-counter market clearance has attracted new interest from international distributors. The company is therefore pleased to announce the addition of Multiple Health Pharma Ltd an OTC and medical products distributor in the Republic of Bangladesh to its ActiPatch distributors, which expands business into the market of the 1.7 billion people in the Indian subcontinent.
Shah Alam, the Managing Director of Multiple Health Pharma Ltd., is confident that ActiPatch products provide them an effective alternative to oral medications and other pain treatmen
FREDERICK, MD--(Marketwired - Feb 28, 2017) - BioElectronics Corporation ( OTC PINK : BIEL )
The following is a statement by BioElectronics Corporation President Andrew J. Whelan:
Dear Fellow Shareholders,
US FDA Over-the Counter Market Clearance
The US FDA has now cleared ActiPatch for over-the-counter sales for the adjunctive treatment of musculoskeletal pain related to: (1) heel pain and (2) osteoarthritis of the knee.
We would have preferred an even broader clearance, but this is a great start. We have an ongoing back pain study in progress at the Oxford University Hospital that should suffice to obtain a broader market clearance in the near future.
Immediate Objectives
BioElectronics Corporation is well poised to capture the paradigm shift in medicine towards electroceuticals. The Company's immediate objectives are:
1. Enter a License and Supply Agreement with a major OTC marketing partner. We seek a partner that has boots on the ground and the managerial and financial resources to execute immediate worldwide retail market penetration. We believe the recent US FDA over-the-counter clearances coupled with the following make us very attractive to major consumer health product companies:
Impressive Efficacy of ActiPatch: 65% of subjects attain a 57% VAS pain score reduction allowing a good night's rest, restoration of daily activities, and an improved quality of life.
Safety profile of ActiPatch: No reported adverse events, no side effects.
ActiPatch's ability to help mitigate the opioid addiction epidemic: surveys that indicate our customers on average have a 50% Reduction in Medication Use, including opioids.
ActiPatch's Exceptional Consumer Acceptance and Demonstrated Marketability: We have developed an innovative approach on how to market an OTC disposable medical device to consumers. The Company's Try & Tell Sales and Marketing Campaign won the OTC Bulletin "Best OTC Marketing Campaign on a Small Budget" award. Since current chronic pain therapies do not meet the need for chronic pain relief, pain sufferers are skeptical of new products. To overcome this skepticism and accelerate product acceptance, we promote and sell a discounted 7-Day Trial ActiPatch device for $9.95 without an on/off switch. Of the trial users, 58% purchased the 720-hour retail units for $30.00, with an average purchase of 1.7 devices within 90 days and 2.7 devices over 1 year.
2. Obtain reimbursement clearance from the National Health System in the UK and Canada. Recently we received a request for additional information on the cost benefit of ActiPatch from the NHS in the UK.
3. Complete the development and testing of the extra strength prescription post-operative chronic wound care device.
4. Complete the clinical trial for back pain at Oxford University Hospital and conduct the migraine headache study. The R&D team has put together a protocol to investigate the efficacy of the ActiPatch in preventing the onset of migraine attacks and/or reducing pain during an attack. The protocol was submitted to Binghamton University's IRB and is awaiting approval. The study will commence in March 2017 and is expected to be completed in June 2017.
This research effort is a collaboration between BioElectronics Corporation, Binghamton University and Eppley Plastic Surgery. Dr. Ken McLeod, from Binghamton University is the principal investigator and a pioneer researcher in the world of bioelectromagnetics. Dr. Barry Eppley, from Eppley Plastic Surgery is a co-investigator and has years of experience treating chronic migraines. Dr. Ian Rawe and Dr. Sree Koneru, both from BioElectronics Corporation, are co-investigators and bring in their clinical and engineering research expertise respectively.
5. Expand clinical evidence on the use of ActiPatch in lieu of or for the reduction of opioids or other narcotics.
6. Continue to seek out international distribution partners. Recently we entered agreements for Lebanon, Bangladesh, and Thailand.
On behalf of the entire staff of BioElectronics, I want to thank all you for your faith in the future of our Company. Please be sure you have "liked" ActiPatch on Facebook and share our posts with your friends and family. You can also let friends and family know that our products can be ordered at www.tryactipatch.com and via Amazon.
Sincerely,
Andrew J. Whelan
President
Andrew Whelan, CEO of BioElectronics Corp. (BIEL), returns to the show with Everett Jolly and they discusses their new FDA approved, non-perscription device for pain relief now on the market
https://audioboom.com/posts/5627325-bioelectronics-corp-s-ceo-andrew-whelan-new-pain-relief-product-gets-fda-approval
Go to Actipatch FB and check reviews...Market will be dominated by ACTIPATCH
https://www.facebook.com/ActiPatch
Finally OTC clearence...
http://www.bielcorp.com/investors/fda-status/
LOL 0.00295/40mil went through 0.0003/160mil bid..
http://ih.advfn.com/stock-market/USOTC/bioelectronics-corp-pc-BIEL/trades
Can we see NHS next week??
http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx